Huron Consulting Group (NASDAQ:HURN) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Huron Consulting Group (NASDAQ:HURN) from a hold rating to a buy rating in a report published on Friday morning.

Several other brokerages have also commented on HURN. Barrington Research increased their price objective on Huron Consulting Group from $120.00 to $128.00 and gave the company an outperform rating in a research report on Wednesday, November 8th. Truist Financial increased their target price on Huron Consulting Group from $100.00 to $130.00 and gave the company a buy rating in a research report on Monday, September 18th. Finally, Benchmark lifted their price target on Huron Consulting Group from $100.00 to $115.00 and gave the company a buy rating in a research note on Friday, July 28th.

Huron Consulting Group Stock Performance

Shares of HURN stock opened at $105.23 on Friday. The stock has a market cap of $1.97 billion, a PE ratio of 27.07 and a beta of 0.59. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.53 and a quick ratio of 1.53. Huron Consulting Group has a one year low of $66.51 and a one year high of $113.31. The stock has a 50-day moving average of $102.51 and a 200-day moving average of $93.02.

Insider Buying and Selling

In other news, Director James H. Roth sold 2,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $98.37, for a total value of $196,740.00. Following the completion of the transaction, the director now owns 76,331 shares of the company’s stock, valued at $7,508,680.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director John Mccartney sold 300 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $101.80, for a total transaction of $30,540.00. Following the completion of the sale, the director now owns 58,119 shares in the company, valued at $5,916,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James H. Roth sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $98.37, for a total value of $196,740.00. Following the sale, the director now directly owns 76,331 shares of the company’s stock, valued at $7,508,680.47. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,300 shares of company stock worth $634,220. Insiders own 2.02% of the company’s stock.

Institutional Investors Weigh In On Huron Consulting Group

A number of institutional investors have recently modified their holdings of HURN. New York State Teachers Retirement System acquired a new stake in Huron Consulting Group in the 1st quarter valued at $30,000. Point72 Asset Management L.P. acquired a new stake in shares of Huron Consulting Group during the 2nd quarter valued at $35,000. West Tower Group LLC bought a new position in shares of Huron Consulting Group during the 2nd quarter valued at $53,000. Money Concepts Capital Corp bought a new position in Huron Consulting Group in the 4th quarter worth $56,000. Finally, Penserra Capital Management LLC acquired a new stake in shares of Huron Consulting Group during the 2nd quarter valued at about $73,000. 92.43% of the stock is owned by institutional investors and hedge funds.

About Huron Consulting Group

Huron Consulting Group Inc, a professional services firm, provides consultancy services in the United States and internationally. It operates through three segments: Healthcare, Education, and Commercial. The Healthcare segment provides advisory services in the areas of financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; financial advisory; software products; and digital solutions, spanning technology and analytic-related services to national and regional health systems, academic and community health systems, public, children's and critical access hospitals, physician practices and medical groups, payors, and long-term care or post-acute providers.